How to taper and discontinue paroxetine (selective serotonin reuptake inhibitor) 10mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Taper and Discontinue Paroxetine 10 mg

Paroxetine should be tapered gradually over several weeks to months, reducing the dose by the smallest increment possible in successive steps of at least several days' duration to minimize withdrawal symptoms. 1

Understanding Paroxetine Discontinuation Syndrome

Paroxetine is associated with a significant discontinuation syndrome, particularly when stopped abruptly. This syndrome can include:

  • Dizziness, fatigue, lethargy, general malaise, myalgias, chills, headaches 1
  • Nausea, vomiting, diarrhea, insomnia 1
  • Imbalance, vertigo, sensory disturbances, paresthesias 1
  • Anxiety, irritability, and agitation 1, 2
  • Abnormal dreams 1
  • Electric shock sensations and tinnitus 2

Recommended Tapering Protocol for Paroxetine 10 mg

Step 1: Preparation

  • Discuss the tapering plan with your healthcare provider before starting 1
  • Consider timing - avoid stressful life periods for discontinuation 1
  • Consider cognitive-behavioral therapy during tapering to increase success rates 1

Step 2: Gradual Dose Reduction

For paroxetine 10 mg specifically:

  • Reduce by the smallest increment possible (e.g., 2.5 mg) at each step 1, 2
  • Allow at least several days (preferably 1-2 weeks) between each dose reduction 1, 3
  • A sample schedule might be:
    • 10 mg daily for 1-2 weeks (current dose)
    • 7.5 mg daily for 1-2 weeks
    • 5 mg daily for 1-2 weeks
    • 2.5 mg daily for 1-2 weeks
    • Then complete discontinuation 3

Step 3: Frequency Reduction (Optional)

  • If symptoms emerge during dose reduction, consider tapering frequency instead 1
  • Example: Take medication every other day or every third day before complete cessation 1

Step 4: Final Discontinuation

  • Continue the lowest possible dose (e.g., 2.5 mg) for at least 1-2 weeks before stopping completely 3
  • Monitor for withdrawal symptoms for several weeks after complete discontinuation 2

Special Considerations

Hyperbolic Tapering

  • Recent evidence suggests that hyperbolic tapering (reducing doses by smaller percentages as the dose gets lower) may be more effective than linear tapering 3
  • This approach recognizes that even small dose reductions at lower doses can produce significant changes in serotonin transporter occupancy 3

Duration of Tapering

  • While guidelines often recommend 2-4 week tapers, longer tapers over months may be more successful in reducing withdrawal symptoms 3
  • Successful tapering may require several weeks to months, especially for patients who have been on paroxetine long-term 1

Monitoring and Management

  • Monitor for withdrawal symptoms, which typically appear within 1-3 days of dose reduction 1
  • If withdrawal symptoms are severe, return to the previous dose temporarily before attempting a slower taper 2
  • Distinguish between withdrawal symptoms (typically occurring within days of dose change) and recurrence of the original condition (typically developing more gradually) 3

Common Pitfalls to Avoid

  • Avoid abrupt discontinuation - this significantly increases risk of withdrawal symptoms 2, 4
  • Don't taper too quickly - tapers that are too rapid show minimal benefits over abrupt discontinuation 3
  • Don't stop at minimum therapeutic doses - tapering to doses lower than minimum therapeutic doses may be necessary to minimize withdrawal 3
  • Don't mistake withdrawal for relapse - withdrawal symptoms typically emerge within days of dose reduction and improve with time, whereas relapse symptoms develop more gradually 3

Remember that paroxetine has a relatively short half-life compared to other SSRIs, making it more likely to cause withdrawal symptoms when discontinued 4. Therefore, a more gradual taper is often required compared to other antidepressants with longer half-lives 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.